Because of the prognostic and predictive roles of CD8+PD-L1+ T cells, CD8+ T cells, and CD68+CD163+ M2 macrophages, it was unsurprising to find that NSCLC patients with a CD8+ high/CD8+PD-L1+ low, CD8+ high/CD68+CD163+ low or CD8+PD-L1+ high/CD8+PD-L1+ low signature had better PFS than patients with the other corresponding signatures (Figure 4). Here, CD8A is linked to non-small cell lung carcinoma.